Posted by Michael Wonder on 29 Jan 2025
Depemokimab accepted for review by the EMA for use in asthma with type 2 inflammation and CRSwNP
28 January 2025 - If approved, depemokimab will be the first ultra long-acting biologic with 6 month dosing.
GSK today announced that the EMA has accepted for review the marketing authorisation application for the use of depemokimab in two indications.
